Payment overview · 2025
General Payments
$1,742.89
100 reported records · 14 companies
Healthcare provider profile · identity verified
Jaesoo Pak, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · CERRITOS, CA · NPI 1023124054
Verified facts
What the public records show
CMS Open Payments records show Jaesoo Pak, M.D. received $1,742.89 in general payments during 2025 across 100 reported records.
Amgen Inc. accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Flector, Jardiance, Kerendia, Licart, Linzess, Prolia, Trelegy Ellipta, Zenpep, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 748 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 398 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALIRESP as an associated drug or biological on 54 records involving 42 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Daliresp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Trelegy Ellipta by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Flector as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Flector by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Licart as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Licart by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ztlido by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $348.04 | 20.0% | 19 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $285.99 | 16.4% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $284.06 | 16.3% | 16 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $195.97 | 11.2% | 13 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $195.81 | 11.2% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.42 | 6.0% | 5 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $56.79 | 3.3% | 2 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $56.22 | 3.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.71 | 2.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.65 | 2.9% | 2 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $47.62 | 2.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.73 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.82 | 1.4% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.06 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,742.89 | 100 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $285.99 | 13 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $265.28 | 15 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $229.11 | 13 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $195.97 | 13 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $195.81 | 20 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $195.81 | 20 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $195.81 | 20 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $188.24 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $159.80 | 9 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $69.60 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $64.52 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $56.79 | 2 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $56.22 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.71 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.65 | 2 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $47.62 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.90 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 748 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 356 | exact normalized | Medicare Part D |
| Flector flector |
2025 | Flector | 2024 | 266 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 94 | exact normalized | Medicare Part D |
| Licart licart |
2025 | Licart | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 123 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 424 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 191 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 179 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
748 | 107 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
123 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
179 | 35 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
424 | 225 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
398 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | DALIRESP open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 42 recipient NPIs · example record 1206139572 |
Daliresp · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
356 | 44 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
94 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
191 | 37 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Flector open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Flector · 2024 Exact normalized brand match · 1 Part D row |
266 | 37 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Licart open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Licart · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 1276 | 152 |
| Dexlansoprazole Dr | Dexlansoprazole | 756 | 131 |
| Creon | Lipase/Protease/Amylase | 748 | 107 |
| Repatha Pushtronex | Evolocumab | 731 | 123 |
| Repatha Sureclick | Evolocumab | 728 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 644 | 223 |
| Clopidogrel | Clopidogrel Bisulfate | 602 | 95 |
| Celecoxib | Celecoxib | 503 | 62 |
| Sucralfate | Sucralfate | 494 | 176 |
| Lidocaine | Lidocaine | 493 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 80 |
| Diclofenac Sodium | Diclofenac Sodium | 430 | 63 |
| Prolia | Denosumab | 424 | 225 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 409 | 58 |
| Brilinta | Ticagrelor | 398 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 371 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 51 |
| Farxiga | Dapagliflozin Propanediol | 356 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 342 | 46 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 312 | 38 |
| Praluent Pen | Alirocumab | 298 | 30 |
| Flector | Diclofenac Epolamine | 266 | 37 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 253 | 28 |
| Losartan Potassium | Losartan Potassium | 242 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 27 |
| Dexilant | Dexlansoprazole | 214 | 75 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 191 | 37 |
| Azithromycin | Azithromycin | 186 | 122 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 183 | 41 |
| Zenpep | Lipase/Protease/Amylase | 179 | 35 |
| Procrit | Epoetin Alfa | 172 | 21 |
| Nateglinide | Nateglinide | 169 | 25 |
| Metformin Hcl | Metformin Hcl | 155 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 21 |
| Linzess | Linaclotide | 123 | 16 |
| Atenolol | Atenolol | 119 | 11 |
| Repaglinide | Repaglinide | 106 | 12 |
| Glimepiride | Glimepiride | 105 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 12 |
| Fluocinonide | Fluocinonide | 95 | 22 |
| Kerendia | Finerenone | 94 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 94 | 13 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 92 | 16 |
| Telmisartan | Telmisartan | 90 | 12 |
| Ozempic | Semaglutide | 85 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 84 | 15 |
| Diclofenac Epolamine | Diclofenac Epolamine | 81 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 70 | 27 |
| Ketoconazole | Ketoconazole | 70 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 68 | 12 |
| Miglitol | Miglitol | 64 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 60 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | suppressed |
| Gabapentin | Gabapentin | 57 | 11 |
| Acarbose | Acarbose | 56 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 56 | suppressed |
| Cialis | Tadalafil | 55 | suppressed |
| Jardiance | Empagliflozin | 55 | suppressed |
| Dutasteride | Dutasteride | 54 | suppressed |
| Pregabalin | Pregabalin | 54 | 11 |
| Carvedilol | Carvedilol | 53 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 11 |
| Tadalafil | Tadalafil | 50 | suppressed |
| Trulicity | Dulaglutide | 48 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 47 | suppressed |
| Procto-Med Hc | Hydrocortisone | 47 | 11 |
| Meclizine Hcl | Meclizine Hcl | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 45 | suppressed |
| Meloxicam | Meloxicam | 44 | suppressed |
| Ztlido | Lidocaine | 43 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 42 | suppressed |
| Saxagliptin-Metformin Er | Saxagliptin Hcl/Metformin Hcl | 41 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 40 | suppressed |
| Furosemide | Furosemide | 38 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 38 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Exelon | Rivastigmine | 36 | suppressed |
| Licart | Diclofenac Epolamine | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Folic Acid | Folic Acid | 30 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Febuxostat | Febuxostat | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 23 | 21 |
| Omeprazole | Omeprazole | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Lisinopril | Lisinopril | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 18 | 18 |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Daliresp | Roflumilast | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Exforge | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Micardis | Telmisartan | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Kombiglyze Xr | Saxagliptin Hcl/Metformin Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,742.89 · 100 records | Amgen Inc. | AIRSUPRA, AREXVY, CREON, EVENITY, FARXIGA, Flector, IBSRELA, JARDIANCE, Kerendia, LINZESS, Licart, PANCREAZE, PROLIA, REPATHA, Sucraid, TRELEGY ELLIPTA, Tirosint, Tymlos, VOQUEZNA, ZENPEP, ZTLido | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error